Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice

被引：2
|
作者：
Grassi, Paolo [1 ]
Verzoni, Elena [1 ]
Mennitto, Alessia [1 ]
Procopio, Giuseppe [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Genitourinary Canc Unit, Via G Venezian 1, I-20133 Milan, Italy
来源：
TRANSLATIONAL ANDROLOGY AND UROLOGY | 2016年 / 5卷 / 06期
关键词：
PHASE-3; TRIAL; OPEN-LABEL; EVEROLIMUS; NIVOLUMAB;
D O I：
10.21037/tau.2016.11.06
中图分类号：
R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
摘要：
引用
收藏
页码：974 / 976
页数：3
相关论文
共 50 条
  • [1] Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?
    Ciccarese, Chiara
    Massari, Francesco
    Tortora, Giampaolo
    [J]. EUROPEAN UROLOGY, 2016, 69 (05) : 969 - 970
  • [2] Cabozantinib: A Review in Advanced Renal Cell Carcinoma
    Zaina T. Al-Salama
    Gillian M. Keating
    [J]. Drugs, 2016, 76 : 1771 - 1778
  • [3] Cabozantinib: A Review in Advanced Renal Cell Carcinoma
    Al-Salama, Zaina T.
    Keating, Gillian M.
    [J]. DRUGS, 2016, 76 (18) : 1771 - 1778
  • [4] Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience
    Manuel Ruiz-Morales, Jose
    Heng, Daniel Y. C.
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (06) : 338 - 347
  • [5] Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
    Tannir, Nizar M.
    Powles, Thomas
    Escudier, Bernard
    Donskov, Frede
    Gruenwald, Viktor
    Sternberg, Cora N.
    Schmidinger, Manuela
    Schoeffski, Patrick
    Szczylik, Cezary
    Peltolta, Katriina
    Nosov, Dmitry
    Melichar, Bohuslav
    Clary, Douglas
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    [J]. KIDNEY CANCER, 2020, 4 (01) : 29 - 39
  • [6] Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial
    Choueiri, T.
    Escudier, B.
    Powles, T.
    Mainwaring, P.
    Rini, B.
    Donskov, F.
    Hammers, H.
    Hutson, T.
    Roth, B.
    Peltola, K.
    Lee, J. L.
    Heng, D.
    Schmidinger, M.
    Borgman-Hagey, A.
    Hessel, C.
    Scheffold, C.
    Schwab, G.
    Tannir, N.
    Motzer, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S709
  • [7] Nivolumab plus cabozantinib for advanced renal cell carcinoma
    Benjamin, David J.
    Nolla, Kyle
    Cella, David
    [J]. FUTURE ONCOLOGY, 2022, 18 (39) : 4351 - 4359
  • [8] Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
    Bergerot, Paulo
    Lamb, Peter
    Wang, Evelyn
    Pal, Sumanta K.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12) : 2185 - 2193
  • [9] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Powles, Thomas
    Motzer, Robert J.
    Escudier, Bernard
    Par, Sumanta
    Kollmannsberger, Christian
    Pikiel, Joanna
    Gurney, Howard
    Rha, Sun Young
    Park, Se Hoon
    Geertsen, Poul F.
    Gross-Goupil, Marine
    Grande, Enrique
    Suarez, Cristina
    Markby, David W.
    Arroyo, Alan
    Dean, Mark
    Choueiri, Toni K.
    George, Daniel
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (06) : 663 - 669
  • [10] Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
    Cella, D.
    Escudier, B.
    Tannir, N.
    Powles, T.
    Donskov, F.
    Peltola, K.
    Schmidinger, M.
    Heng, D.
    Mainwaring, P.
    Hammers, H.
    Lee, J-L.
    Rini, B. I.
    Roth, B.
    Baer, J.
    Mangeshkar, M.
    Scheffold, C.
    Hutson, T.
    Pal, S.
    Motzer, J.
    Choueiri, T. K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
12345